1 / 34

Developing a web-based portal to improve chemotherapy dose selection: A pilot study

Developing a web-based portal to improve chemotherapy dose selection: A pilot study. T. May Pini, MD, MPH Division of Hematology/Oncology September 16, 2010. Breast Cancer. 2010 in the U.S. ~200,000 new cases of breast cancer ~40,000 deaths. Adjuvant Chemotherapy.

hal
Download Presentation

Developing a web-based portal to improve chemotherapy dose selection: A pilot study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Developing a web-based portal to improve chemotherapy dose selection: A pilot study T. May Pini, MD, MPH Division of Hematology/Oncology September 16, 2010

  2. Breast Cancer • 2010 in the U.S. • ~200,000 new cases of breast cancer • ~40,000 deaths

  3. Adjuvant Chemotherapy • Treatment given after surgery to increase the chances of cure • Regimens include 2 or more chemotherapy agents • Typically given for 4 to 8 “cycles” • 1st cycle dose based on clinical trials • Responsive dose reductions, due to therapy-related toxicities, may be required for subsequent cycles

  4. Chemotherapy Dose • Body surface area (BSA) calculated using weight & height • Chemotherapy doses calculated using BSA & standard chemotherapy protocols • Example: “AC” x 4 cycles • Doxorubicin dose (mg) = 60 mg/m2 x BSA • Cyclophosphamide dose (mg) = 600 mg/m2 x BSA Full dose calculated by using actual body weight Slide modified from slide courtesy of Dr. Griggs

  5. Background: The dose problem • Full doses of adjuvant chemotherapy needed to achieve optimal disease-free survival (DFS) & overall survival (OS)

  6. Background: The dose problem • No evidence toxicity greater in obese patients • Side effects less common among obese patients, even when fully dosed • ~ 40% of overweight & obese breast cancer patients receive reduced doses

  7. Background: Role of the medical oncologist Decisions about giving/receiving adjuvant chemotherapy shared between oncologist & patient Dose selection solely decided upon by medical oncologist

  8. Practice Variation in the Use of First Cycle Dose Reduction among Overweight and Obese Patients, n = 919 Ann Intern Med 2005, slide courtesy of Dr. Griggs

  9. Potential influences on 1st cycle dose selection • Practice Characteristics • Size of practice • Competing demands • Availability of practice guidelines • Availability of standardized chemotherapy orders • Daily volume of encounters • Opportunity costs (workload from treatment toxicities) • On-call frequency • Availability of fellows, NP’s, PA’s • Pharmacy policies and pharmacist knowledge/behavior • Nursing knowledge/behavior First cycle DOSE SELECTION • Physician Characteristics • Years in practice • Oncology board certification • Extent of subspecialization • INTERNAL FACTORS • Knowledge, attitudes, beliefs • Perceived Risk:Benefit ratio of treatment with full weight based dosing

  10. Potential influences on 1st cycle dose selection • Practice Characteristics • Size of practice • Competing demands • Availability of practice guidelines • Availability of standardized chemotherapy orders • Daily volume of encounters • Opportunity costs (workload from treatment toxicities) • On-call frequency • Availability of fellows, NP’s, PA’s • Pharmacy policies and pharmacist knowledge/behavior • Nursing knowledge/behavior First cycle DOSE SELECTION • Physician Characteristics • Years in practice • Oncology board certification • Extent of subspecialization • INTERNAL FACTORS • Knowledge, attitudes, beliefs • Perceived Risk:Benefit ratio of treatment with full weight based dosing

  11. Potential influences on 1st cycle dose selection • INTERNAL FACTORS • Knowledge, attitudes, beliefs • Perceived Risk:Benefit ratio of treatment with full weight based dosing • External factors modifying perceived Risk:Benefit ratio • Professional society practice guidelines • CME • Peer-reviewed literature • Beliefs of opinion leaders about dose selection • Beliefs of colleagues about dose selection • Prior experience with treatment toxicities • Patient characteristics modifying perceived Risk:Benefit ratio • BMI • Comorbidities • Age • Sex • Degree of social support • Patient concerns regarding dose selection

  12. Potential influences on 1st cycle dose selection • Not much known about oncologist knowledge, attitudes, & beliefs regarding use of full weight-based chemotherapy dosing in curative intent settings • Not much known about effects of individual oncologist & practice characteristics on use of full weight-based chemotherapy doses

  13. Background: Audit and feedback • Definition (Cochrane 2009) • Summary of clinical performance of health care • May include recommendations for clinical action • Used to improve practice behaviors • Effectiveness improved when feedback delivered with specific suggestions for improvement (Hysong 2009) • May be effective in improving medical oncologist dose selection practice

  14. Background: Using the web • Interactive web-based technology ideal platform to reach medical oncologists • Advantages • Target wide range of practice settings • Cost-effective • Modifiable

  15. Specific Aims • Develop web-based system to (1) survey medical oncologists about dose selection practices, (2) provide tailored feedback regarding optimal dosing of adjuvant chemotherapy for obese women with breast cancer • Assess effectiveness of tailored feedback intervention on improvement in use of full weight dosing of adjuvant chemotherapy for obese breast cancer patients • Investigate physician and practice characteristics associated with reduced versus full weight dosing in treatment of cancer in curative intent settings

  16. Medical oncologists & hematologists (N = 200) • Recruited from practices participating in the Michigan Breast Oncology Quality Initiative (MiBOQI) • Excluding: • Bone marrow transplant • Only non-malignant hematologic conditions Subjects & Recruitment: Baseline Day 1: Invitation to participate via letter from MiBOQI Director Week 2: Non-participants contacted by phone and faxed duplicate letter if requested Weeks 3-4: Non-responders emailed up to 2 times with request to complete survey

  17. Subjects & Recruitment: Follow-up Physicians who see breast cancer patients 3 mo. after completion of baseline survey: Email to complete a brief follow-up survey Follow-up weeks 1-2: Non-responders will be contacted up to 2 additional times via email requesting completion of the follow-up survey

  18. Tailored Feedback Intervention • Medical oncologists who see breast cancer patients will be asked how they dose obese patients when treating breast cancer in the adjuvant setting • Full doses are calculated using actual body weight • What is the most appropriate way to dose obese breast cancer patients? Please check ONE. • Actual body weight • Ideal body weight • Adjusted ideal body weight • Capping body surface area at 2.___m2. Please fill in the blank (e.g. 2.0 m2, 2.2 m2, etc.) • Other (please specify) _________________

  19. Tailored Feedback Intervention • Feedback to these oncologists will be given immediately after completion of baseline survey, based on responder type (full-dose vs. other) • Full-dose group will receive reinforcement that practice supported by evidence & summary of evidence available • Under-dosing group will receive feedback that practice is not supported by current evidence & summary of evidence

  20. Tailored Feedback Intervention Feedback also tailored to degree of agreement or disagreement with specific concerns regarding use of full weight-based dosing: • Survival • Short-term hematologic toxicities • Short-term non-hematologic toxicities • Long-term toxicities

  21. Tailored Feedback Intervention

  22. Tailored Feedback Intervention

  23. Analyses • Study design • Pretest posttest, no control group (intervention reaches entire target population) • Primary outcome • Proportion of oncologists reporting full weight dosing after intervention • Secondary outcome • Proportion of oncologists switching to full weight dosing for breast cancer & switching to full weight dosing for other solid tumors

  24. Exploratory Analyses • Logistic regression model • Dependent variable • Full weight dosing at baseline, dichotomous • Independent variables • Physician factors (demographics, degree of specialization, enrollment of pts onto clinical trials, pt volume, frequency of call, availability of physician extenders, receiving personal feedback about practice patterns) • Practice (university affiliation, cooperative group participation, availability of std chemo orders and/or integrated guidelines, participation in an improvement program)

  25. Thank you!

More Related